Malaria Prevention Advances: Monoclonal Antibodies Targeting Plasmodium falciparum as a Complementary Strategy for Elimination in Sub-Saharan Africa

Despite substantial progress in malaria control over the past two decades, malaria caused by Plasmodium falciparum remains a leading cause of morbidity and mortality in sub-Saharan Africa, particularly in young children.1 Achievement of malaria elimination will require complementary interventions that target different stages of the parasite lifecycle and can be implemented in different transmission settings.2 In addition to vector control, chemoprevention, and vaccination, monoclonal antibodies targeting parasite antigens have emerged as a promising strategy for malaria prevention.

A recent commentary published in The Lancet highlights the potential of antibody-based approaches for malaria prevention in intense perennial transmission settings. The article, titled “[Comment] Antibody-based malaria prevention in an intense perennial transmission setting,” discusses emerging evidence on monoclonal antibodies designed to prevent Plasmodium falciparum infection by targeting the circumsporozoite protein (CSP), a key antigen on the surface of malaria sporozoites.

Research cited in the commentary indicates that monoclonal antibodies such as CIS43LS and L9LS have demonstrated protective efficacy in clinical trials. A single dose of CIS43LS has been shown to provide durable, sterile protection against Plasmodium falciparum infection in adults, with efficacy rates of 87.4% at a dose of 40 mg/kg, and 77.0% at 10 mg/kg over a six-month malaria season, as measured by highly sensitive polymerase chain reaction (PCR) detection of parasitic RNA.

Further analysis revealed that CIS43LS also reduced gametocytemia — the presence of transmissible parasite stages — with 87.7% efficacy at the higher dose and 73.0% at the lower dose over the same period. These findings suggest that such antibodies not only prevent infection but may also interrupt transmission by blocking the development of parasites capable of infecting mosquitoes.

Another monoclonal antibody, L9LS, has been evaluated for safety and efficacy in preventing malaria in children aged 6 to 10 years exposed to seasonal transmission. While initial results show high efficacy in this group, the commentary notes that L9LS remains untested in younger children and in settings of perennial, year-round malaria transmission — contexts where the burden of disease is often highest.

The authors emphasize that achieving malaria elimination will require tools effective across diverse epidemiological settings, including areas with intense, continuous transmission. Monoclonal antibodies offer a potential advantage due to their direct mechanism of action, long half-life, and suitability for administration via infrequent dosing — qualities that could complement existing strategies such as seasonal malaria chemoprevention and vaccination.

While the results are promising, the commentary underscores important gaps in current knowledge. Key among these is the lack of data on the use of monoclonal antibodies in very young children, who bear the greatest mortality burden from malaria, and in regions where transmission occurs throughout the year rather than seasonally. Ongoing and future studies will need to address these populations and settings to determine the full potential of this intervention.

Experts involved in the research caution that monoclonal antibodies are not intended to replace existing malaria control measures but could serve as an additional layer of protection, particularly in high-risk groups or during peak transmission periods. The approach may be especially valuable in contexts where drug resistance limits the effectiveness of chemopreventive agents or where vaccine coverage and durability remain suboptimal.

As research advances, the focus will shift toward optimizing dosing regimens, assessing long-term safety, and evaluating cost-effectiveness in real-world deployment scenarios. The ultimate goal, as articulated in the commentary, is to integrate monoclonal antibodies into a broader, multifaceted strategy aimed at interrupting transmission and reducing the unacceptable toll of malaria on vulnerable populations.